|
Studienakronym |
Krankheitsentität  |
Vollständiger Titel / Beschreibung |
Status |
|
|
TRACE |
|
Treatment of chemo-refractory viral infections after allogeneic stem cell transplantation with multispecific T cells against CMV, EBV and AdV: A phase III, prospective, multicentre clinical trial
|
 |
 |
|
TRAM |
Bösartige Neubildung des Gehirns
[C71.-]
Sekundäre bösartige Neubildung des Gehirns und der Hirnhäute
[C79.3]
ZNS Tumore
|
Differenzierung zwischen Tumorprogress und Therapie bedingter Änderungen nach Strahlentherapie mittels Contrast Clearance Assessment
|
|
|
|
|
TRANSFORM CRAD001A2433 |
Zustand nach Nierentransplantation
[Z94.0]
|
A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation.
|
|
|
|
|
TransitionCHF |
Sonstige und nicht näher bezeichnete Krankheiten des Kreislaufsystems
[I99]
|
Keine Angabe
|
|
|
|
|
TransitionCHF |
Sonstige Studien
|
Systolic Dysfunction to Congestive Heart Failure Cohort Study
|
|
|
|
|
TraSki |
|
Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function
|
|
|
|
|
TREAT-ME 1 |
Krebs des Verdauungstrakts
|
Treatment of Advanced Gastrointestinal Cancer in a Phase I/II trial with modified autologous MSC_apceth_101
|
 |
|
|
|
TREAT-SVDs |
Schlaganfall, nicht als Blutung oder Infarkt bezeichnet
[I64]
|
EffecTs of Amlodipin and other Blood PREssure Lowering Agents on Microvascular FuncTion in Small Vessel Diseases
|
|
|
|
|
TRIANGLE |
Blutkrebs (z.B. Leukämie, Lymphome)
|
Autologous Transplantation after a Rituximab/Ibrutinib/ara-c containing induction in generalized mantle cell lymphoma - a randomized european MCL Network trial
|
 |
|
|
|
TRIANGLE |
Sonstige nicht follikuläre Lymphome
[C83.8]
Blutkrebs (z.B. Leukämie, Lymphome)
|
Autologous Transplantation After a Rituximab/Ibrutinib/Ara-C-
Containing INduction in Generalized Mantle-Cell Lymphoma –
a Randomized European MCL Network Trial
|
|
|
|
|
TRICC-C |
Bösartige Neubildung am Rektosigmoid, Übergang
[C19]
Blutkrebs (z.B. Leukämie, Lymphome)
|
A multicenter, randomized, phase II trial: BIBF 1120 vs. placebo in patients receiving oxaliplatin plus fluorouracil and leucovorin (mFOLFOX6) for advanced, chemorefractory metastatic colorectal cancer (mCRC)
|
|
|
|
|
Trilogy CO39262 |
Bösartiges Melanom der Haut, nicht näher bezeichnet
[C43.9]
Krebserkrankungen der Haut
|
A PHASE III, DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS COBIMETINIB AND VEMURAFENIB VERSUS PLACEBO PLUS COBIMETINIB AND VEMURAFENIB IN PREVIOUSLY UNTREATED BRAF V600 MUTATION-POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA
|
|
|
|
|
TRIO-022 (A5481008) |
Brustkrebs
|
A Randomized, Multicenter, Doube-blind Phase III Study of PD 0332991 (Oral CDK 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole For The Treatment Of Postmenopausal Women With ER(+), HER2 (-) Breast Cancer Who Have Not Received Any Prior Systemic Anti-Cancer Treatment For Advanced Disease
|
|
|
|
|
TRIO33_NATALEE |
Brustkrebs
|
A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]:
|
|
|
|
|
TROPICAL-ACS |
Sonstige Studien
|
TESTING RESPONSIVENESS TO PLATELET INHIBITION ON CHRONIC ANTIPLATELET TREATMENT FOR ACUTE CORONARY SYNDROMES - (TROPICAL-ACS) TRIAL.
A PROSPECTIVE, RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL,NON-INFERIORITY, MULTICENTER TRIAL OF A 12 MONTH VS. A SHORT-TERM PLATELET FUNCTION TESTING GUIDED PRASUGREL THERAPY IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING CORONARY STENTING
|
|
|
|
|
TRUSTS |
Bösartige Neubildung sonstigen Bindegewebes und anderer Weichteilgewebe
[C49.-]
Sarkome (Knochen- und Weichteilkrebs)
|
A phase IIb/III multicenter study comparing the efficacy of Trabectedin administered as a 3 hour or 24 hour infusion to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma
|
|
|
|
|
TUD-PEMAZA-068 |
Blutkrebs (z.B. Leukämie, Lymphome)
|
MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse
|
|
|
|
|
TUD-RELA02-048 |
Sonstige Studien
Blutkrebs (z.B. Leukämie, Lymphome)
|
Behandlung des drohenden hämatologischen Rezidivs von Patienten mit MDS oder AML mit Azacitidin (Vidaza®) im Hämalog (26.05.2021 SE)
|
|
|
|
|
TUD-RELA02-048 |
Akute myeloblastische Leukämie [AML]
[C92.0-]
Blutkrebs (z.B. Leukämie, Lymphome)
|
Behandlung des drohenden hämatologischen Rezidivs von Patienten mit MDS oder AML mit Azacitidin (Vidaza®)
|
|
|
|
|
U31287-A-U203 DAIICHI |
Bösartige Neubildung der Nasenhöhle und des Mittelohres
[C30.-]
Bösartige Neubildung der Trachea
[C33]
Kopf-Hals-Tumore
Unbekannt
|
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study
of Patritumab (U3-1287) in Combination with Cetuximab plus
Platinum-Based Therapy in First Line Setting in Subjects with
Recurrent or Metastatic Squamous Cell Carcinoma of the Head
and Neck
|
|
|
|
|
Vaccibody VB N-01 |
Sonst. urogenitale Tumore z.B. Blase,Niere
Sonst. urogenitale Tumore z.B. Blase,Niere
|
An open labelled first human dose phase 1/2a study to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO immunotherapy in patients with locally advanced or metastatic melanoma, NSCLC, clear renal cell carcinoma, urothelial cancer or squamous cell carcinoma of head and neck, who did not reach complete responses with current standard of care immune checkpoint blockade
|
|
|
|
|
Varianz |
Magentumor
|
Vorhersage von Ansprechen oder Resistenz durch Identifizierung von Biomarkern beim Adenokarzinom des Magens und des gastroösophagealen Übergangs innerhalb einer nicht-interventionellen Studie und zielgerichteter Therapie mit Trastuzumab
|
|
|
|
|
VB N-01 |
Sonst. urogenitale Tumore z.B. Blase,Niere
Sonst. urogenitale Tumore z.B. Blase,Niere
Krebserkrankungen der Haut
Lungenkrebs
Sonstige Tumore
|
An open labelled first human dose phase 1/2a study to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO immunotherapy in patients with locally advanced or metastatic melanoma, NSCLC, clear renal cell carcinoma, urothelial cancer or squamous cell carcinoma of head and neck, who did not reach complete responses with current standard of care immune checkpoint Blockade - Melanom Kohorte geschlossen
Z-Nr.: 347
TrackCell Tablets located in III Med Studiensekretariat
Second Pharmajet handed over to Urologie Department on 26Sep2019
|
|
|
|
|
Venezia-CIP-001 |
Bösartige Neubildung der Cervix uteri
[C53.-]
Gynäkologische Tumore
|
Multi-center prospective observational Clinical Follow-Up study Advanced Gynecological Applicator - Venezia Configuration
|
|
|
|
|
VesPa |
Schwindel und Taumel
[R42]
|
Therapie der Vestibularisparoxysmie mit Carbamazepin: eine prospektive randomisierte Placebo-kontrollierte doppelblinde multizentrische Studie
|
|
|
